Get started
Author

James R. Porter

Observed names: J. R Porter, J.R. Porter, James Porter, James R Porter, James R. Porter
ORCID: 0000-0002-6633-9475
Observed ORCID: 0000-0002-6633-9475
OpenAlex ID: A5103028267
PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
2013 · David G. Winkler, Kerrie L. Faia, et al. · Chemistry & Biology · 266
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
2006 · Jens R. Sydor, Emmanuel Normant, et al. · Proceedings of the National Academy of Sciences · 230
Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90
2006 · Jie Ge, Emmanuel Normant, et al. · Journal of Medicinal Chemistry · 194
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
2010 · James R Porter, Christian C Fritz, et al. · Current Opinion in Chemical Biology · 182
Semisynthetic Cyclopamine Analogues as Potent and Orally Bioavailable Hedgehog Pathway Antagonists
2008 · Martin R. Tremblay, Marta Nevalainen, et al. · Journal of Medicinal Chemistry · 110
Ansamycin Inhibitors of Hsp90: Natures Prototype for Anti-Chaperone Therapy
2009 · James Porter, Jie Ge, et al. · Current Topics in Medicinal Chemistry · 72
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · Jessica J. Lin, Joshua C. Horan, et al. · Cancer Discovery · 69
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2022 · Alexander Drilon, Joshua C. Horan, et al. · Cancer Discovery · 55
An efficient synthesis of indane-derived bis(oxazoline) and its application to hetero Diels–Alder reactions on polymer support
2003 · Michio Kurosu, James R Porter, et al. · Tetrahedron Letters · 33
Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation
2021 · Henry E. Pelish, Anupong Tangpeerachaikul, et al. · Cancer Research · 26
Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies
2012 · Ian W. Flinn, Steven M. Horwitz, et al. · Blood · 23
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activityin vivo
2009 · Mark Douglas, Alice R. Lim, et al. · Molecular Cancer Therapeutics · 15
Development of a Multi Kilogram-Scale, Tandem Cyclopropanation Ring-Expansion Reaction en Route to Hedgehog Antagonist IPI-926
2016 · Brian C. Austad, Andrew B. Hague, et al. · Organic Process Research & Development · 8
Formation of Carbon-Carbon Bonds Using Iron Tricarbonyl-(η4-cyclobutadienyl)-Stabilized Carbonium Ions
1999 · James R. Porter · Synthesis · 7
Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation
2021 · Henry E. Pelish, Anupong Tangpeerachaikul, et al. · Cancer Research · 4
Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma.
2004 · Vito J. Palombella, Emmanuel Normant, et al. · Blood · 4
148 POSTER Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors
2008 · C. Fritz, B. Tillotson, et al. · European Journal of Cancer Supplements · 3
Pharmaceutical development of IPI‐504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
2010 · James R. Porter, Julian Adams, et al. · Drug Development Research · 2
ChemInform Abstract: Ti‐Catalyzed Regio‐ and Enantioselective Synthesis of Unsaturated α‐Amino Nitriles, Amides and Acids. Catalyst Identification Through Screening of Parallel Libraries.
2000 · James R. Porter, Wolfgang G. Wirschun, et al. · ChemInform · 2
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025 · Alexander Drilon, Joshua C. Horan, et al.
PDF
Data from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · Jessica J. Lin, Joshua C. Horan, et al.
Supplementary Figures S1-S17 from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · Jessica J. Lin, Joshua C. Horan, et al.
Data from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2023 · Alexander Drilon, Joshua C. Horan, et al.
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2023 · Alexander Drilon, Joshua C. Horan, et al.
PDF
Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of 17-AAG and Potent Inhibitor of Hsp90
2008 · J. R Porter, R. Ahn, et al. · AACR Education book
Works count: 29
Citation count: 1,294
H-index: 12
I10-index: 12
Year
Topic
Type